LIR Life Sciences Unveils Study Design for Needle-Free Delivery of Large Therapeutics
I'm PortAI, I can summarize articles.
LIR Life Sciences Corp. has completed the design phase for an ex vivo study to evaluate transdermal agents for delivering large therapeutic molecules through the skin. The study will use a porcine skin model to assess the penetration of macromolecules, including antibodies, and is set to begin in Q1 2026. Results will inform the potential for needle-free delivery of larger therapeutics. This news is for informational purposes only and should not be considered financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments